Labgenius | search
Click here to view Labgenius news from 60+ newspapers.
Bookmark or Share- LabGenius raises £35 million led by M Ventures. - LabGeniusLabGenius, a drug discovery company pioneering the use of machine learning for the discovery of novel therapeutic antibodies, today announced that it has closed a £35 million Series B financing round. The investment brings LabGenius’ total funding to date to £58 million.
- LabGenius Debuts T-cell Engager Optimisation Capability That Yields ...LabGenius’ ML-driven platform can be used for the simultaneous optimisation of potency, efficacy, tumour cell selectivity and developability. In this demonstration study, LabGenius’ platform was used to co-optimise VHH-based HER2xCD3 TCEs, which resulted in the delivery of novel highly selective, high-performing molecules with non-intuitive ...
- Dr Edwin Moses - LabGeniusChairman. Edwin Moses was Chief Executive Officer of Ablynx NV until its agreed takeover by Sanofi for $4.8 billion in 2018. He was CEO of Ablynx for more than 12 years and built it from a small R&D-focused organisation into a 500-person commercial-ready business.
- Single-domain Antibody Conference, Paris - LabGeniusGet in touch at partnerships@labgeni.us to explore how we could expedite discovery of better antibody therapeutics together.
- Immuno-oncology Summit | Poster Presentation - LabGeniusGet in touch at partnerships@labgeni.us to explore how we could expedite discovery of better antibody therapeutics together.
More
